Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
Current Signal: SELL (auto-tracking)
-0.21% $67.20
America/New_York / 17 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 3 427.43 mill |
EPS: | -0.120 |
P/E: | -560.00 |
Earnings Date: | Apr 29, 2024 |
SharesOutstanding: | 51.00 mill |
Avg Daily Volume: | 0.993 mill |
RATING 2024-04-17 |
---|
A |
Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Sell | |
Return On Equity: | Neutral | |
Return On Asset: | Buy | |
DE: | Neutral | |
P/E: | Strong Buy | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | n/a | |||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -560.00 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-2.52x |
Company: PE -560.00 | industry: PE 222.16 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 66.69 - 67.73 ( +/- 0.77%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-31 | Sama Rinda | Buy | 28 000 | Common Stock |
2024-01-31 | Sama Rinda | Sell | 17 500 | Performance-Based Restricted Stock Units |
2024-01-31 | Noblett Karen | Buy | 27 500 | Common Stock |
2024-01-31 | Noblett Karen | Sell | 11 288 | Common Stock |
2024-01-31 | Noblett Karen | Sell | 15 000 | Performance-Based Restricted Stock Units |
INSIDER POWER |
---|
-1.52 |
Last 98 transactions |
Buy: 597 788 | Sell: 539 127 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $67.20 (-0.21% ) |
Volume | 0.582 mill |
Avg. Vol. | 0.993 mill |
% of Avg. Vol | 58.59 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $67.72 | N/A | Active |
---|
Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.